OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock Feb 6, 2018
OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study Jan 18, 2018
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab Dec 14, 2017
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform Nov 28, 2017
